Kisspeptin regulates gonadotropin-releasing hormone secretion in gonadotropin-releasing hormone/enhanced green fluorescent protein transgenic rats.

Xue H, Yang C, Ge X, Sun W, Li C, Qi M

Neural regeneration research1 Jan 2013Cited by 3 (Europe PMC)

PMID25206487PMCIDPMC4107516DOI10.3969/j.issn.1673-5374.2013.02.009PepBankPUB-25206487

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In GnRH/EGFP transgenic rats, kisspeptin‑10 injection into the arcuate nucleus and medial preoptic area significantly increased luteinizing hormone level.
In plain wordsIn rats, kisspeptin‑10 injected into two brain areas raised luteinizing hormone.
Peptide
Kisspeptin-10
Outcome
IncreaseLH level after KP-10 injection into arcuate nucleus and medial preoptic area
Study
ratn: not reported in source
GnRH/EGFP transgenic rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1, 10 and 100 pM · injection into arcuate nucleus and medial preoptic areaAs given in this study (rat).
Source sentences
Summary
a significant increase in luteinizing hormone level was observed after kisspeptin-10 injection into the arcuate nucleus and medial preoptic area.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were injected with 1, 10, or 100 pM kisspeptin-10, a peptide derived from full-length kisspeptin, into the arcuate nucleus and medial preoptic area, and with the kisspeptin antagonist peptide 234 into the lateral cerebral ventricle.
Report a problemFND-2520648701
02AnimalAnimal study (in vivo)Efficacy outcome
In GnRH/EGFP transgenic rats, LH levels during the first hour of arcuate nucleus infusion were greater with 100 pM kisspeptin‑10 than with 10 pM.
In plain wordsIn rats, a higher kisspeptin‑10 dose in the brain gave more luteinizing hormone than a lower dose.
Peptide
Kisspeptin-10
Outcome
IncreaseLH level by KP-10 dose during arcuate nucleus infusion
Study
ratn: not reported in source
GnRH/EGFP transgenic rats
Comparator
10 pM kisspeptin-10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 and 100 pM · infusion into arcuate nucleus · first hourAs given in this study (rat).
Source sentences
Summary
The results of an enzyme-linked immunosorbent assay showed that luteinizing hormone levels during the first hour of kisspeptin-10 infusion into the arcuate nucleus were significantly greater in the 100 pM kisspeptin-10 group than in the 10 pM kisspeptin-10 group.
Report a problemFND-2520648702

Studies that did not test the peptide alone1

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

03AnimalNot a test of Kisspeptin-10 aloneAnimal study (in vivo)Efficacy outcome
In GnRH/EGFP transgenic rats, the kisspeptin antagonist peptide 234 injected into the lateral cerebral ventricle suppressed pulsatile LH secretion.
In plain wordsIn rats, a kisspeptin blocker injected into the brain stopped pulsed release of luteinizing hormone.
Peptide
Kisspeptin-10
Outcome
DecreasePulsatile LH secretion after kisspeptin antagonist peptide 234
Study
ratn: not reported in source
GnRH/EGFP transgenic rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
The results of immunohistochemical staining revealed that pulsatile luteinizing hormone secretion was suppressed after injection of antagonist peptide 234 into the lateral cerebral ventricle
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-2520648703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.